LeMaitre Vascular (NASDAQ:LMAT) Given “Outperform” Rating at Barrington Research

Barrington Research reissued their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report published on Friday morning,Benzinga reports. The brokerage currently has a $95.00 price objective on the medical instruments supplier’s stock.

Several other research analysts have also issued reports on LMAT. Wells Fargo & Company reduced their target price on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Stock Up 1.2%

Shares of LeMaitre Vascular stock opened at $92.94 on Friday. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $2.11 billion, a P/E ratio of 40.06, a PEG ratio of 2.04 and a beta of 0.72. The firm’s 50 day moving average price is $85.54 and its 200-day moving average price is $88.14. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $105.55.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently modified their holdings of LMAT. Mercer Global Advisors Inc. ADV raised its holdings in LeMaitre Vascular by 11.5% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after purchasing an additional 371 shares during the period. NewEdge Advisors LLC raised its stake in shares of LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after buying an additional 139 shares during the period. Empowered Funds LLC purchased a new position in shares of LeMaitre Vascular during the 4th quarter valued at approximately $289,000. nVerses Capital LLC acquired a new stake in LeMaitre Vascular in the 4th quarter valued at $234,000. Finally, Voloridge Investment Management LLC increased its holdings in LeMaitre Vascular by 70.0% in the 4th quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after acquiring an additional 25,901 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.